A district judge has reportedly refused to block sales of a generic blood thinner made by Sandoz (NYSE:NVS) (NASDAQ:MNTA), which puts Sanofi-Aventis' (NYSE:SNY) efforts to protect its bests-selling blood thinner Lovenox at an immediate disadvantage. Sanofi sued the FDA in late July following its approval of Sandoz's efforts to make a generic form of the special heparin, called enoxaparin. Sanofi's argument was based on the fact that the enoxaparin made by Sandoz is not exactly the same as Lovenox and therefore shouldn't be approved or marketed as the same block-buster drug in generic form. Lovenox generated revenue of billion for Sanofi in 2009. SmarTrend is bullish on shares of Novartis and our subscribers were alerted to buy on June 10, 2010 at .16. The stock has risen 7.2% since the alert was issued.
No comments:
Post a Comment